Ceri E. Oldreive

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma.

Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma.

Journal: Haematologica
Published: October 04, 2023

SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.

SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.

Journal: Nature genetics
Published: March 09, 2023

TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Journal: Blood
Published: March 26, 2020

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL.

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL.

Journal: Blood
Published: April 22, 2019

PALB2 variant status in hematological malignancies - a potential therapeutic target?

PALB2 variant status in hematological malignancies - a potential therapeutic target?

Journal: Leukemia & lymphoma
Published: January 08, 2019

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Journal: British journal of haematology
Published: June 24, 2017

Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts.

Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts.

Journal: Oncotarget
Published: March 15, 2017

USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.

USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.

Journal: Blood
Published: December 21, 2016

NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma.

NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma.

Journal: Oncotarget
Published: April 11, 2016

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Journal: Blood
Published: July 18, 2015

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

Journal: Blood
Published: May 08, 2015

T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.

T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.

Journal: Disease models & mechanisms
Published: April 10, 2015
Showing 1-12 of 17

Last Updated: 09/26/2026